Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...

Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...